ArticleParasites & vectors2025
Leishmania infantum-specific production of IL-17a in stimulated blood from dogs in different clinical stages of leishmaniosis.
Article in Parasites & vectors, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLeishmania infantum infection progression in dogs depends on the interaction between the parasite and the host's immune response. The adaptive immune response, primarily mediated by T-helper 1 lymphocytes, promotes an effective reaction by increasing cytokines such as interferon-gamma (IFN-γ). In addition, interleukin-17a (IL-17a) plays a role in controlling parasite growth through inducible nitric oxide synthase activation. However, limited data exist on IL-17a production in dogs at different disease stages. This study aimed to evaluate L. infantum-specific IL-17a production in blood samples from dogs with varying clinical stages of leishmaniosis and to assess its correlation with disease severity, humoral response, and IFN-γ concentrations.
methodsIn total, 65 dogs were included; 10 healthy seronegative and 55 sick dogs, classified into three groups according to the LeishVet clinical stages, were studied. IFN-γ and IL-17a concentrations were measured using a sandwich enzyme-linked immunosorbent assay (ELISA) after performing a L. infantum-specific cytokine release whole-blood assay following stimulation with soluble L. infantum antigen.
resultsNo significant differences in IL-17a concentration were observed between healthy and all sick dogs (P = 0.77). Dogs in stage I presented higher IL-17a concentrations than dogs in stages II and III. However, the difference was only statistically significant when compared with stage III (P = 0.044). Regarding IFN-γ, all sick dogs demonstrated higher concentrations than healthy dogs (P = 0.003). Stage I dogs also exhibited higher IFN-γ concentrations compared with healthy dogs (P = 0.0002) and with dogs in stage II (P = 0.016) and III (P = 0.016). Stage II dogs showed higher IFN- γ concentrations than healthy dogs (P = 0.03). All dogs studied presented a positive correlation between IFN-γ and IL-17a concentrations (Spearman's r: 0.54, P < 0.0001). Regarding all the sick dogs, a negative correlation was found between IFN-γ concentration and antibody levels (Spearman's r: -0.41, P = 0.002), and between IL-17a concentration and antibody levels (Spearman's r: -0.27, P = 0.044). There was a positive correlation between IFN-γ and IL-17a concentration (Spearman's r: 0.61, P < 0.0001).
conclusionsThis study demonstrates that IL-17a production is increased in mild disease when compared with more advanced clinical stages, acting as a possible "resistance" marker. However, IL-17a seems to be less reliable as a marker when compared with IFN-γ.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.